The FDA has granted priority review to an anti-clotting drug from Daiichi Sanyko Co. Ltd. and Eli Lilly and Co. The pill, prasugrel, could compete with Plavix if approved.
Published in Brief:
|Vice President of Regulatory Affairs||
|Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX||
|Santa Clara, CA|
|Senior Director, Biostatistics||